TY - JOUR
T1 - Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh
AU - Khanam, Farhana
AU - Babu, Golap
AU - Rahman, Nazia
AU - Liu, Xinxue
AU - Rajib, Nazmul Hasan
AU - Ahmed, Shams Uddin
AU - Hossen, Md Ismail
AU - Biswas, Prasanta Kumar
AU - Kelly, Sarah
AU - Thesis-Nyland, Katherine
AU - Mujadidi, Yama
AU - McMillan, Nigel A.J.
AU - Pollard, Andrew J.
AU - Clemens, John D.
AU - Qadri, Firdausi
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2023/5/5
Y1 - 2023/5/5
N2 - A cluster-randomized trial of Vi-TT was conducted in Dhaka, Bangladesh, using JE vaccine as the control. A subset of 1,500 children were randomly selected on 2:1 basis (Vi-TT vs JE) to assess immune response. Blood was collected before vaccination, and on days 28, 545 and 730 post-vaccination and plasma anti-Vi-IgG response was measured. A robust, persistent antibody response was induced after single dose of Vi-TT, even after 2 years of vaccination. While there is no accepted serological antibody threshold of protection, analyzing the antibodies of children who received Vi-TT provides evidence that may later be useful in predicting population protection.
AB - A cluster-randomized trial of Vi-TT was conducted in Dhaka, Bangladesh, using JE vaccine as the control. A subset of 1,500 children were randomly selected on 2:1 basis (Vi-TT vs JE) to assess immune response. Blood was collected before vaccination, and on days 28, 545 and 730 post-vaccination and plasma anti-Vi-IgG response was measured. A robust, persistent antibody response was induced after single dose of Vi-TT, even after 2 years of vaccination. While there is no accepted serological antibody threshold of protection, analyzing the antibodies of children who received Vi-TT provides evidence that may later be useful in predicting population protection.
KW - Bangladeshi children
KW - CRT-TCV
KW - Long-term immune response
UR - http://www.scopus.com/inward/record.url?scp=85152559992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85152559992&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2023.04.014
DO - 10.1016/j.vaccine.2023.04.014
M3 - Article
C2 - 37061369
AN - SCOPUS:85152559992
SN - 0264-410X
VL - 41
SP - 3137
EP - 3140
JO - Vaccine
JF - Vaccine
IS - 19
ER -